251 related articles for article (PubMed ID: 16638622)
1. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment.
Pesaresi M; Lovati C; Bertora P; Mailland E; Galimberti D; Scarpini E; Quadri P; Forloni G; Mariani C
Neurobiol Aging; 2006 Jun; 27(6):904-5. PubMed ID: 16638622
[TBL] [Abstract][Full Text] [Related]
2. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
[TBL] [Abstract][Full Text] [Related]
3. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
[TBL] [Abstract][Full Text] [Related]
5. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H
Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538
[TBL] [Abstract][Full Text] [Related]
6. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease.
Guidi I; Galimberti D; Lonati S; Novembrino C; Bamonti F; Tiriticco M; Fenoglio C; Venturelli E; Baron P; Bresolin N; Scarpini E
Neurobiol Aging; 2006 Feb; 27(2):262-9. PubMed ID: 16399211
[TBL] [Abstract][Full Text] [Related]
7. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.
Gurol ME; Irizarry MC; Smith EE; Raju S; Diaz-Arrastia R; Bottiglieri T; Rosand J; Growdon JH; Greenberg SM
Neurology; 2006 Jan; 66(1):23-9. PubMed ID: 16401840
[TBL] [Abstract][Full Text] [Related]
8. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
9. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease.
Kim TS; Lim HK; Lee JY; Kim DJ; Park S; Lee C; Lee CU
Neurosci Lett; 2008 May; 436(2):196-200. PubMed ID: 18378084
[TBL] [Abstract][Full Text] [Related]
10. Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort.
Blasko I; Jungwirth S; Jellinger K; Kemmler G; Krampla W; Weissgram S; Wichart I; Tragl KH; Hinterhuber H; Fischer P
J Psychiatr Res; 2008 Sep; 42(11):946-55. PubMed ID: 18155247
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment.
Cammarata S; Borghi R; Giliberto L; Pardini M; Pollero V; Novello C; Fornaro M; Vitali A; Bracco L; Caltagirone C; Bossù P; Odetti P; Tabaton M
J Alzheimers Dis; 2009; 18(2):267-71. PubMed ID: 19584444
[TBL] [Abstract][Full Text] [Related]
12. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.
Irizarry MC; Gurol ME; Raju S; Diaz-Arrastia R; Locascio JJ; Tennis M; Hyman BT; Growdon JH; Greenberg SM; Bottiglieri T
Neurology; 2005 Nov; 65(9):1402-8. PubMed ID: 16275827
[TBL] [Abstract][Full Text] [Related]
13. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment.
Mufson EJ; Chen EY; Cochran EJ; Beckett LA; Bennett DA; Kordower JH
Exp Neurol; 1999 Aug; 158(2):469-90. PubMed ID: 10415154
[TBL] [Abstract][Full Text] [Related]
14. Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment.
Mamo JC; Jian L; James AP; Flicker L; Esselmann H; Wiltfang J
Ann Clin Biochem; 2008 Jul; 45(Pt 4):395-403. PubMed ID: 18583625
[TBL] [Abstract][Full Text] [Related]
15. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.
Song F; Poljak A; Smythe GA; Sachdev P
Brain Res Rev; 2009 Oct; 61(2):69-80. PubMed ID: 19464319
[TBL] [Abstract][Full Text] [Related]
16. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
Buchhave P; Janciauskiene S; Zetterberg H; Blennow K; Minthon L; Hansson O
Neurosci Lett; 2009 Jan; 450(1):56-9. PubMed ID: 18996438
[TBL] [Abstract][Full Text] [Related]
17. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.
Fukumoto H; Tennis M; Locascio JJ; Hyman BT; Growdon JH; Irizarry MC
Arch Neurol; 2003 Jul; 60(7):958-64. PubMed ID: 12873852
[TBL] [Abstract][Full Text] [Related]
18. Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees.
Ertekin-Taner N; Graff-Radford N; Younkin LH; Eckman C; Adamson J; Schaid DJ; Blangero J; Hutton M; Younkin SG
Genet Epidemiol; 2001 Jul; 21(1):19-30. PubMed ID: 11443731
[TBL] [Abstract][Full Text] [Related]
19. Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype.
De Jonghe C; Cras P; Vanderstichele H; Cruts M; Vanderhoeven I; Smouts I; Vanmechelen E; Martin JJ; Hendriks L; Van Broeckhoven C
Neurobiol Dis; 1999 Aug; 6(4):280-7. PubMed ID: 10448055
[TBL] [Abstract][Full Text] [Related]
20. Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels.
Papaliagkas VT; Anogianakis G; Tsolaki MN; Koliakos G; Kimiskidis VK
Dement Geriatr Cogn Disord; 2009; 28(1):30-5. PubMed ID: 19628938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
